Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ambien CR Generics Need Extra Bioequivalence Tests, Sanofi Argues To FDA

Executive Summary

Sanofi-Aventis is requesting that FDA require additional bioequivalence tests for generic versions of its insomnia product Ambien CR (zolpidem extended-release)

You may also be interested in...

Sleep Agents Update Warnings As FDA Seeks Further Study Of “Complex” AEs

Questions about the safety of drugs in the sedative-hypnotic class could warrant additional clinical trials to further evaluate the complex sleep-related behaviors associated with the drugs, FDA said in announcing stronger warnings for the class March 14

Ambien CR Approval Includes Sleep Maintenance, Long-Term Use

The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents

Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales

Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts